The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...
(RTTNews) - Jacobio Pharma (1167.HK) announced that it has entered into a strategic agreement with AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) for its proprietary Pan-KRAS inhibitor, JAB-23E73. Under the ...
The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73 ...
LONDON, UK and BUDAPEST, HUNGARY, Oct. 9, 2025 /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results